HS 235
Alternative Names: HS-235Latest Information Update: 16 Aug 2023
At a glance
- Originator 35Pharma
- Class Obesity therapies; Recombinant fusion proteins
- Mechanism of Action Activin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Obesity
- Research Musculoskeletal disorders
Most Recent Events
- 15 Jun 2023 Preclinical trials in Obesity in Canada (SC), prior to June 2023
- 15 Jun 2023 Pharmacodynamics data from a preclinical trial in Obesity presented at the 105th Annual Meeting of the Endocrine Society (ENDO-2023)
- 29 Nov 2022 HS 235 is available for licensing as of 29 Nov 2022. https://35pharma.com/#6 (35Pharma pipeline, November 2022)